中国医院用药评价与分析2025，Vol.25Issue(4)：458-462,5.DOI:10.14009/j.issn.1672-2124.2025.04.017
低氧诱导因子脯氨酰羟化酶抑制剂治疗肾性贫血的临床综合评价
Clinical Comprehensive Evaluation of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor in the Treatment of Anemia in Chronic Kidney Disease
摘要
Abstract
OBJECTIVE:To quantitatively evaluate hypoxia-inducible factor prolyl hydroxylase inhibitor(HIF-PHI),so as to provide reference and basis for individualized treatment of different patients.METHODS:Based on A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(the Second Edition),comprehensive digital evaluation of two HIF-PHI(enarodustat and roxadustat)was conducted from five aspects such as pharmaceutical characteristics,efficacy,safety,economy,and other attributes.RESULTS:The evaluation scores of enarodustat and roxadustat were more than 70 points,while enarodustat tablets(4 mg)had the highest overall score.At present,enarodustat is only approved for the treatment of anemia in non-dialysis patients in China,and is not recommended for patients with liver insufficiency.Roxastat can be used for these populations.The efficacy of enarodustat in increasing hemoglobin was weaker than that of roxadustat,but the efficacy of decreasing hepcidin level was greater than that of roxadustat.Roxadustat was recommended for patients with moderate and severe anemia.Enarodustat was selected for patients with poor iron tolerance.Enarodustat may be more suitable for patients who need to protect residual renal function.Roxadustat may be more suitable for patients with hyperlipidemia.Enarodustat had fewer drug interactions.Economy of enarodustat was slightly better than that of roxadustat.CONCLUSIONS:Enarodustat and roxadustat each have advantages in different attributes.In clinical application,drugs can be selected according to the characteristics of patients.关键词
恩那度司他/罗沙司他/药品遴选评价/肾性贫血Key words
Enarodustat/Roxadustat/Drug selection and evaluation/Anemia in chronic kidney disease分类
医药卫生引用本文复制引用
关丽叶,田冬冬,吴玉佩,段宝京,方灵芝..低氧诱导因子脯氨酰羟化酶抑制剂治疗肾性贫血的临床综合评价[J].中国医院用药评价与分析,2025,25(4):458-462,5.基金项目
河北省医学科学研究课题(No.20190402) （No.20190402）
